Vancouver, BC, May 13, 2024--AbCellera announced financial results for the first quarter of 2024. Total revenue was $10.0 million, compared to $12.2 million in Q1 2023. Net loss was $40.6 million compared to net loss of $40.1 million in Q1 2023.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, May 9, 2024--AbCellera, Viking Global Investors, and ArrowMark Partners announced that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, March 12, 2024--AbCellera and Biogen Inc. ammounced that they have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, February 26, 2024--AbCellera announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, February 21, 2024--AbCellera announced financial results for the full year 2023. The company reported total revenue of $38 million, compared to $485 million in FY 2022 and generated a a net loss of $146.4 million, compared to net earnings of $158.5 million in 2022.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, November 28, 2023--AbCellera presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, November 6, 2023--AbCellera and Prelude Therapeutics announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, November 3, 2023--AbCellera announced financial results for the third quarter of 2023. The company earned $6.6 million in total revenue and generated a net loss of $28.6 million, compared to total revenue of $101 million and net earnings of $26.6 million in Q3 2022.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, September 26, 2023--AbCellera announced that it has expanded its existing multi-target collaboration with Regeneron to discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Vancouver, BC, September 19, 2023--AbCellera announced that it has entered into a strategic collaboration with Incyte to discover and develop therapeutic antibodies in oncology.
Vancouver (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 2012
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.